ArticleFrontiers in oncology2024
Case report: Illustrating associated malignancies in Paget's disease using contrast-enhanced mammography.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The following presentation explores the diagnostic potential of Contrast-Enhanced Mammography (CEM) in evaluating and managing Paget's Disease (PD) of the breast, particularly as an alternative or complementary tool to Magnetic Resonance Imaging (MRI) in cases where MRI is contraindicated or inconclusive. Clinical cases: Two clinical cases of PD diagnosed at our Breast Imaging Division between January and May 2024 were analyzed using CEM. These cases involved imaging techniques, including Digital Mammography (DM), Breast Ultrasound (US), MRI and CEM, alongside histopathological confirmation through nipple-areolar complex (NAC) punch biopsies. CEM identified disease extensions and NAC involvement that was not evident in conventional imaging in both cases. CEM findings influenced surgical decisions, leading to total mastectomies with reconstruction instead of conservative approaches. The cases highlighted CEM's sensitivity and ability to delineate the disease extent comparable to MRI. Discussion and conclusions: PD often presents diagnostic challenges due to frequent associations with underlying malignancies that are undetectable by standard imaging. While MRI is the gold standard, its limitations, such as costs, contraindications, and false positives, warrant alternative methods. CEM demonstrated utility in diagnosing and staging PD, offering benefits in patient acceptability, cost, and sensitivity comparable to MRI. CEM is a promising diagnostic and planning tool for PD management, especially in MRI-infeasible cases. More extensive multicentric studies will be needed to validate CEM's role in this context. CEM could enhance PD diagnostic workflows and treatment strategies, significantly impacting clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.